View Exam | PowerPak

1. Which of the following treatment options has demonstrated decreased mortality when treating patients with COVID-19?

A. Dexamethasone B. Hydroxychloroquine C. Tocilizumab D. Remdesivir

2. Which of the following dosing regimens is the usual dose for remdesivir in adult patients?

A. 200 mg intravenously once daily for 5–10 days B. 200 mg intravenously (loading dose), followed by 100 mg IV once daily for total of 5–10 days C. 200 mg intravenously (loading dose), followed by 100 mg IV once daily for 3 days D. 100 mg intravenously once daily for 5–10 days

3. As recommended in COVID-19 treatment guidelines from the National Institutes of Health, which of the following patients would be the best candidate for remdesivir therapy who has laboratory-confirmed SARS-CoV-2 infection?

A. Outpatient receiving treatment at an infusion center B. Hospitalized patient who does not currently require supplemental oxygen C. Hospitalized patient who requires supplemental oxygen on medicine floor D. Hospitalized, critically ill patient in an intensive care unit who requires mechanical ventilation

4. As recommended in COVID-19 treatment guidelines from the National Institutes of Health, which of the following patients would be the best candidate for dexamethasone therapy who has laboratory-confirmed COVID-19?

A. Outpatient who is asymptomatic B. Hospitalized patient who does not currently require supplemental oxygen C. Outpatient who has symptoms D. Critically ill patient in an intensive care unit who requires mechanical ventilation

5. As recommended in COVID-19 treatment guidelines from the Infectious Diseases Society of America, optimal outcomes with convalescent plasma are achieved in

A. Outpatients who are early in course of the infection B. Inpatients who are early in course of the infection C. Severely ill patients who are mechanically ventilated D. None of the above; patients should be enrolled in clinical trials of convalescent plasma

6. Study of which of the following agents within the ACTIV-3 trial was recently terminated by the National Institutes of Health?

A. LY-CoV555 B. BX-CoV585 C. PZ-CoV355 D. AZ-CoV190

7. How many SARS-CoV-2 vaccines are currently approved by FDA for administration in the United States?

A. 0 B. 1 C. 2 D. 3

8. How many treatment options are currently approved by FDA for the management of COVID-19?

A. 0 B. 1 C. 2 D. 3

9. Which of the following agents is currently recommended for use in clinical trials but not for general use because of a lack of clinical evidence supporting use as well as concerns of overall broad immunosuppression?

A. Baricitinib B. Hydroxychloroquine C. Remdesivir D. Dexamethasone

10. Which of the following statements best describes the recommendations of the National Institutes of Health guidelines regarding the role of corticosteroids other than dexamethasone in the management of COVID-19?

A. Data specific to hydrocortisone are equivalent to dexamethasone for efficacy. B. In patients who are ready for discharge, transition from intravenous dexamethasone to oral prednisone is recommended if the full 10-day course has not been completed. C. Methylprednisolone has demonstrated increased mortality compared with other corticosteroids that have been studied for treatment of SARS-CoV-2 infection. D. Alternative corticosteroids such as prednisone can be used if dexamethasone is not available.